EWTX · Edgewise Therapeutics, Inc.

Track EWTX — free

$39.68 -0.62 (-1.54%)

Russell 2000 member Rebalance outlook locked

Market Cap

$4.27B

108.60M

Volume · Oct 6 550.97K Avg daily vol (3M) 1.35M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+157.5%

Trailing year

Short interest

8.8%

Latest settlement · 8.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +16%

above

Price vs 50-day avg −6%

below

RSI (14) 43

neutral

MACD trend Negative

52-week position 76%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −6%

trailing

6-month return +22%

trailing

YTD return +62%

this year

Relative strength +10%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $43 › 200d $35 — 50d above 200d

Institutional flow Distributing

2 of 228 funds reported for Sep 30 · net -73 sh shares

Insider flow Distributing

Net -$785.0K over 90 days · 100% sells

Short interest Rising

8.79% of float · ▲ +2.1% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

228 holders — near 3-yr high, broad support

Squeeze score 69

elevated · 0–100

Fundamentals

Poor

EPS growth −12%

Y/Y

Free cash flow $-144.1M

Quant / Vol

risk profile

Very High

Volatility 75%

annualized · 1-yr

Max drawdown −21%

past year

ATR 5.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+16% Bullish

Price vs 50-day avg

−6% Bearish

RSI (14)

43 Neutral

MACD trend

Negative Bearish

52-week position

76% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $43 › 200d $35 — 50d above 200d

Institutional flow Distributing

2 of 228 funds reported for Sep 30 · net -73 sh shares

Insider flow Distributing

Net -$785.0K over 90 days · 100% sells

Short interest Rising

8.79% of float · ▲ +2.1% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

228 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $15 Now $40 · 76% Range high $48

vs 200-day avg +16% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EWTX Edgewise Therapeutics, Inc. this stock	$4.27B	+62.4%	—	—	8.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

228

% held: 110.2%
Reported: 2 of 228
Top holder: ORBIMED ADVISORS LLC

Held Float

View

Held by Funds

Fund positions

231

View

Short & Settlement

Short Interest Rising

Shares short

9.5M

Days to cover: 8.0d
Change: +197.7K sh

View

Short Volume

Short vol %

45%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

226

Value: $9.9K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

47.2%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$785.0K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-167.8M

EPS diluted: $-1.63

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 11

View

Proposed Sales

Value

$127.2K

Shares: 2.9K
Filed: Aug 13, 2026

View

Exempt Offerings

Offering

$95.0M

Filed: Dec 10, 2020

View

Earnings & Events

Webcasts

Last webcast

May 13, 2024

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
EWTX	+1.3%	-6.4%	+21.5%	-0.7%	+62.4%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	+0.1%	-7.0%	+10.0%	-2.3%	+48.8%

Key facts CIK 1710072 CUSIP 28036F105 13F (30d) 6 filings 6 filers Visit website Investor relations

EWTX · Edgewise Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance